Overview

Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yantai Yuhuangding Hospital
Criteria
Inclusion Criteria:

1. Patients with treatment-refractory advanced solid cancer can not accept operation;

2. Age 18 to 75 years;

3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points;

4. estimate survival > 3 months;

5. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count (PLT)≥ 80×109/L;
Alanine amino transferase (ALT) and aspartate amino transferase (AST)≤ 2 times of
normal upper value; Serum Cr ≤ 2 normal upper value;

6. Without any other malignant disease;

7. With more than one scalable lesions;

8. Patients Voluntary attempt, and informed consent;

9. Women of child-bearing potential must have a negative pregnancy test because of the
potentially dangerous effects of the preparative chemotherapy on the fetus.

Exclusion Criteria:

1. Patients who do not conform to the inclusion criteria;

2. Patients with uncontrolled infection; underlying disease that was severe or
life-threatening (such as uncontrolled brain metastasis );

3. Patients who were pregnant or lactating;

4. ECOG perform status ≥ 2;4.

5. Other situations that the researchers considered unsuitable for this study (such as
mental illness, drug abuse, etc.)